Lilly Lowers List Price of Insulin Lispro
Effective Jan. 1 2022, the move brings the price to 2008 levels.
Eli Lilly plans to lower the list price of Insulin Lispro Injection in the United States by an additional 40% effective Jan. 1, 2022. The new list price will apply to all of Lilly’s non-branded insulins, including Insulin Lispro Injection, an alternative to Lilly’s Humalog U-100. This will bring the list price down to 2008 levels.
The new list price for Insulin Lispro Injection will be $82.41 for individual vials and $159.12 for a pack of five pens, which is 70% less than Humalog U-100 counterparts.
Patients can fill their monthly prescription for $35 through the Lilly Insulin Value Program for people with commercial insurance or who are uninsured. Last year, Lilly initiated the $35 copay program. To access this price, patients must enroll in the Lilly Insulin Value Program. Anyone with or without commercial insurance is eligible, and the program covers most Lilly insulins including all Humalog formulations.
David A. Ricks
Patients with Medicare Part D plans are not eligible for a co-pay card, but Lilly offers a separate program called the Senior Savings Model for those in Medicare Part D plans.
“Half list-priced Insulin Lispro Injection has been adopted by a third of Humalog U-100 consumers. We hope this additional 40% cut can expand affordable insulin to more people with diabetes,” David A. Ricks, Lilly’s chairman and CEO, said in a statement
Diabetes Management & Telehealth with Leslie Kolb
June 11th 2020Association of Diabetes Care and Education Specialists, chief science and practice officer, Leslie Kolb chats with MHE Associate Editor Briana Contreras in MHE's newest podcast Tuning into the C-Suite about diabetes management and how it's affected by the use of telehealth, especially during the current and trying times of the COVID-19 pandemic.
Listen
FDA Advisory Committee Votes Down Sotagliflozin in Type 1 Diabetes and CKD
November 1st 2024Committee members said there was uncertainty around sotagliflozin in patients with kidney disease. The FDA is currently reviewing the oral therapy as an adjunct to insulin to help control glycemic levels in adults with type 1 diabetes and chronic kidney disease. The agency’s goal date is Dec. 20, 2024.
Read More
ICER Gives Cell Therapy for Post-Transplant Complications High Rating
Published: October 31st 2024 | Updated: October 31st 2024ICER has given tabelecleucel a rating of A, indicating the T cell therapy for Epstein-Barr virus related post-transplant lymphoproliferative disease has a high certainty of substantial net health benefit and would be cost-effective if priced between $143,900 and $273,700.
Read More
